A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.
Dahmani A, de Plater L, Guyader C, Fontaine JJ, Berniard A, Assayag F, Beuzeboc P, Marangoni E, Némati F, Poupon MF, Pasik C, Oudard S, Decaudin D.
Dahmani A, et al. Among authors: pasik c.
Anticancer Drugs. 2010 Nov;21(10):927-31. doi: 10.1097/CAD.0b013e32833db887.
Anticancer Drugs. 2010.
PMID: 20827173